

DAFTAR PUSTAKA

1. Cunningham L, Bloom, Dashe. *Hypertensive Disorders*. Williams Obstetric 25 ed. New York: Mc Graw Hill; 2018. p.1086-8
2. ACOG. Task Force on Hypertension in Pregnancy. In: James M Roberts PAA, George Bakris, John R. Barton, editor. *Classification of Hypertensive Disorders*. Washington DC: ACOG; 2013. p. 13-73
3. HKFM POGI. *Diagnosis dan Tata Laksana Pre-Eklamsia*. 2016
4. Saito S. *Preeclampsia, Basic, Genomic, and Clinical*. Springer. 2018
5. Adhi Pribadi. *Preeklamsia “Stoppable”*. Sagung Seto. 2019
6. Myatt L, Roberts JM. Preeklamsia: Syndrome or Disease? *Curr Hypertens Rep*. 2015;17(11).
7. Roberts J. 2009. Pregnancy related hypertension. In (Creasy R, Resnik R, Iams JD, editors) *maternal-fetal medicine: principles and practice 6*. Philadelphia: Saunders Elsevier, pp 650–88
8. Bellos I, Karageorgiou V, Kapnias D, Karamanli KE, Siristatidis C. The role of interleukins in preeklamsia: A comprehensive review. *Am J Reprod Immunol*. 2018;80(6):1–21.
9. Chatterjee P, Kopriva SE, Chiasson VL, Young KJ, Tobin RP, Newell-Rogers K, et al. Interleukin-4 deficiency induces mild preeklamsia in mice. *J Hypertens*. 2013;31(7):1414–23.
10. Julia M. Orshal, Raouf A. Khalil, *Reduced Endothelial NO-cGMP-Mediated Vascular Relaxation and Hypertension in IL-6-Infused Pregnant Rats*. 2004
11. Lopez, J.P. 2001. Preeklamsia from Epidemiological Observations to Molecular Mechanisms. *Brazilian Journal of Medicine and Biological Research*. 34;1227-35
12. Stillman, I.E., Karumanchi, S.A. 2007. In *The Glomerular Injury of Preeklamsia Pathophysiology of the Renal Biopsy*. *J Am Soc. Nephrol*. 18: 2281-84

13. Roudsari, F.V., Ayati, S., Ayatollahi, H., Esmacily, H., Hasanzadeh, M., Shahabian, M., Ali, L.P. 2009. Comparison of maternal serum Tumor Necrosis Factor-alpha (TNF- α) in severe and mild preeklamsia versus normal pregnancy. *Iranian Journal of Reproductive Medicine*. Vol.7: No.4. pp: 153-156.
14. Afshari, J.T., Ghomian, N. 2005. Determination of Interleukin-6 and Tumor Necrosis Factor-Alpha Concentrations in Iranian-Khorasanian Patient with Preeklamsia. *BMC Pregnancy and Childbirth*. 5-14
15. Mawardi, Ganie RA, Lumbranraja SN. Levels of interleukin-6 and tumor necrosis factor alpha in pregnant patients with preeklamsia and patients with normal pregnancy. *Indones J Clin Pathol*. 2019;25(2):199–201.
16. Xiao JP, Yin YX, Gao YF, Lau S, Shen F, Zhao M, et al. The increased maternal serum levels of IL-6 are associated with the severity and onset of preeklamsia. *Cytokine* [Internet]. 2012;60(3):856–60. Available from: <http://dx.doi.org/10.1016/j.cyto.2012.07.039>
17. Ekapatria, Christofani. 2012. Placental growth factor is lower in early-onset preeclampsia, while tumor necrosis factor does not show any difference between early and late onset preeclampsia. inajog.com
18. Lei H, Zhiling Y, Al E. Antepartum or Immediate Postpartum Renal Biopsi Preeklamsia of Pregnancy: new Morphologic and Clinical Findings. *Int J Clin Exp Pathol*. 2014;7(8):5129–43.
19. Walker J, Morley L. Pre-Eclampsia. In: *BMJ best practice*. 2019. p. 1–46.
20. Anne C, Samantha BJ, Peter DV et al. Redefining Preeklamsia Using Placenta - Derived Biomarkers Hypertension. 2013;61:932–42.
21. Redman CWG, Staff AC. Preeklamsia, biomarkers, syncytiotrophoblast stress, and placental capacity. *Am J Obstet Gynecol*. 2015;213(4):S9.e1-S9.e4.
22. Chahine KM, Sibai BM. Chronic Hypertension in Pregnancy: New Concepts for Classification and Management. *American journal of perinatology*. 2018.
23. Gao Q, Tang J, Li N, Liu B, Zhang M, Sun M, et al. What is precise pathophysiology in development of hypertension in pregnancy? *Precision*

medicine requires precise physiology and pathophysiology. Drug discovery today. 2018;23(2):286-99.

24. Gathiram P, Moodley J. Pre-eclampsia: its pathogenesis and pathophysiology. Cardiovascular Journal Of Africa. 2016;27(2):71-9.
25. Magee LA, von Dadelszen P. State-of-the-Art Diagnosis and Treatment of Hypertension in Pregnancy. Mayo Clinic proceedings. 2018;93(11):1664-77.
26. POGI(PerkumpulanObstetriGinekologiIndonesia). Panduan Praktek Klinis Hipertensi Dalam Kehamilan. 2018. diakses Oktober 2018.
27. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy hypertension. 2018;13:291-310.
28. Zhang J-M, An J. Cytokines, Inflammation and Pain. Int Anesth Clin. 2007;45(2):27-37.
29. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2):503-8.
30. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta - Mol Cell Res. 2014;1843(11):2563-82.
31. Abbas, A.K., Lichtman, A.H. 2005. Cytokines. In: Cellular and Molecular Immunology. 5th. Ed. Philadelphia: W.B. Saunders Company. 11: 243-254.
32. Liles W, Van Voorhis W. Review : Nomenclature and Biologic Significance of Cytokines Involved in Inflammation and the Host Immune Response. J Infect Dis Infect Dis. 1995;172(6):1573-80.
33. Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics. 2010;5(1):30-55.
34. Commins SP, Borish L, Steinke JW. Immunologic messenger molecules: Cytokines, interferons, and chemokines. J Allergy Clin Immunol. 2010;125(2 SUPPL. 2):S53-72.

35. Jazayeri JA, Carroll GJ, Vernallis AB. Interleukin-6 subfamily cytokines and rheumatoid arthritis: Role of antagonists. *Int Immunopharmacol.*2010;10(1):1–8.
36. Wei LH, Kuo ML, Chen CA, Chou CH, Cheng WF, Chang MC, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. *Oncogene.* 2001;20(41):5799–809.
37. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Bräsen JH, et al. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. *Hypertension.* 2005;45(4 SUPPL.):742–6.
38. LaMarca B, Speed J, Ray LF, Cockrell K, Wallukat G, Dechend R, et al. Hypertension in response to IL-6 during pregnancy: Role of AT1-receptor activation. *Int J Interf Cytokine Mediat Res.* 2011;3(1):65–70.
39. La Marca B, Brewer J, Wallace K. IL-6-induced pathophysiology during pre-eclampsia: Potential therapeutic role for magnesium sulfate? *Int J Interf Cytokine Mediat Res.* 2011;3(1):59–64
40. Olusi, S.O., Diejomaoh, M., Omu, A., Abdulaziz, A., Prabha, K., George, S. 2000. Interleukin in Preeclampsia. *Original Articles Anals of Saudi Medicine.* Departemen of Pathology Obsterics and Gynecology Faculty of Medicine, Kuwait University. Vol. 20: no 1.
41. LaMarca, B.D., Ryan, M.J., Granger, J.P. 2007. Pathophysiology of Hypertention During Peeclampsia: Role of Inflammatory Cytokines. in *Current Hypertension reviews.* Bentham Science Publishers Ltd.3, 69-74
42. Conrad, K.P., Benyo, D.F. 1997. Placental cytokines and the pathogenesis of preeclampsia. *Am J Reprod.Immun.* 37(3): 240-249.
43. Lockwood, C.J., Yen, C.F. 2008. Preeclampsia Related Inflammatory Cytokines Regulate Interleukin-6 Expression in Human Decidual Cells. *American Journal of Pathology.*172:1571-79
44. Zak P, Soucek M. Correlation of Tumor Necrosis Factor Alpha, Interleukin 6 and Interleukin 10 with Blood Pressure, Risk of Preeclampsia and Low Birth Weight in Gestational Diabetes *Physiol Res.* 2019;68:395-408.

45. Roza Sriyanti, Johanes C. Mose,Netti Suharti. The Difference in Maternal Serum Hypoxia-Inducible Factors-1 α Levels between Early Onset and Late-Onset Preeclampsia. *Maced J Med Sci.* 2019 Jul 15; 7(13): 2133–2137.
46. Vitoratos N, Economou E, Lavazzo C, Panoulis K, Creatsas G. Maternal serum levels of TNF-Alpha and IL-6 long after delivery in preeclamptic and normotensive pregnant women. *Hindawi Publishing Corporation.* 2010;2010:1-6.
47. Ozler A, Turgut A, Sak ME, Evsen MS, Soydinc HE, Evliyaoglu O, et al. Serum levels of neopterin, tumor necrosis factor-alpha and interleukin-6 in preeclampsia: relationship with disease severity *Eur Rev Med Pharma Sci.* 2012;16:1707-12.
48. Husen, D &Polin, A. 2012. Factors Influencing Maternal Mortality from Severe Preeclampsia and Eclampsia.*MajObstetGinekolog Indonesia* 2012; 36-2: 90-4
49. Denantika O, Serudji J, Revilla G. 2015. Hubungan Status Gravida dan Usia Ibu terhadap Kejadian Preeklampsia di RSUP Dr. M. Djamil Padang Tahun 2012-2013. *Jurnal Kesehatan Andalas* 4(1).
50. El Shahat AM, Ahmed AB, Ahmed MR, Mohamed HS. 2013. Maternal serum leptin as a marker of preeclampsia. *Arch Gynecol Obstet* 288(6):1317-1322.
51. *Ario Danianto, Ernawati. Perbedaan Kadar IL-10 pada Preeklampsia Tipe Dini dan Lambat* *Majalah Obstetri & Ginekologi*, Vol. 23 No. 3 September - Desember 2015 : 106-111
52. Anna W 'ojtowicz ,Małgorzata Zembala-Szczerba, Dorota Babczyk, Monika Kołodziejczyk-Pietruszka, Olga Lewaczy nska, Hubert Huras. Early- and Late-Onset Preeclampsia: A Comprehensive Cohort Study of Laboratory and Clinical Findings according to the New ISHHP Criteria. *International Journal of Hypertension.* Volume 2019, Article ID 4108271, 9 pages <https://doi.org/10.1155/2019/4108271>
53. Migraci Tosun, Handan Celik, Bahattin Avci, Erhan Yavuz, Tayfun Alper & Erdal Malatyalioglu. Maternal and umbilical serum levels of interleukin-6, interleukin-8, and tumor necrosis factor- α in normal pregnancies and in

pregnancies complicated by preeclampsia. Department of Obstetrics and Gynecology and Department of Biochemistry, Ondokuz Mayıs University, Turkey (Received 1 November 2009; accepted 11 March 2010)

54. Ajith A. The role of peripheral natural killer cells in immunocompromised pre-eclamptic and normotensive pregnant black South Africans. PhD dissertation, University of KwaZulu-Natal, Durban, 2016.

